A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients — NOVA-II

Hand-Foot Skin Reaction (HFSR) Clinical Trial

Official title:
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Status Active, not recruiting

Clinical Trial Summary

Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients. The main purpose of this study is to evaluate the safety and efficacy of OQL011 compared to vehicle ointment in treating patients with moderate to severe VEGFRi-associated HFSR. This study will also identify an optimal dosage for Phase III study and explore the pharmacokinetics profile of OQL011 in HFSR patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hand-Foot Skin Reaction (HFSR)

Clinical Trial Details

NCT number	NCT04088318
Study type	Interventional
Source	OnQuality Pharmaceuticals (USA) LLC
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 9, 2019
Completion date	June 2024

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04242927` - A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions	Phase 2
	Terminated	`NCT04071756` - Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions	Phase 2